Sponsors (28)
The bill strengthens and speeds safety oversight of infant formula—improving detection, investigation, and uniform testing standards to better protect babies—at the cost of higher compliance burdens, potential short-term supply disruptions, and procedural/privacy concerns for manufacturers.
Parents and infants: more comprehensive and uniform testing and inspection of infant formula (domestic and imported) reduces the chance that contaminated formula reaches babies.
Parents and caregivers: manufacturers must report positive contamination results to FDA within one business day and FDA must quickly notify Congress, enabling faster government awareness and response to safety threats.
Hospitals and public-health systems: retention of records of positive test results improves inspections and investigations into contamination sources, strengthening outbreak response and oversight.
Parents and infants (and other consumers): stricter testing and rapid-reporting requirements could prompt more recalls or product holds, risking short-term reductions in formula availability and supply disruptions.
Infant formula manufacturers (especially smaller producers) and consumers: increased testing, recordkeeping, and rapid-reporting will raise compliance costs that may be passed on to consumers as higher prices.
FDA and health-system stakeholders: a 90-day deadline to issue final regulations could strain agency resources and lead to rushed rulemaking or implementation challenges.
Based on analysis of 2 sections of legislative text.
Directs FDA to require pathogen and environmental testing, rapid reporting, record retention, and uniform inspection standards for all infant formula, with final rules due in 90 days.
Official title: To amend the Federal Food, Drug, and Cosmetic Act to establish standardized pathogen and microorganism testing of infant formula products and manufacturing facilities, to mandate notification of specific positive tests and inspection classifications, and for other purposes.
Introduced March 9, 2026 by Rosa L. Delauro · Last progress March 9, 2026
Requires the FDA to tighten infant formula manufacturing rules by adding mandatory pathogen and environmental testing, specifying testing frequency and zones, requiring one-business-day notification to FDA for positive results, retaining records of positives, and applying consistent inspection standards to all formula regardless of origin. The bill directs FDA to finalize implementing regulations within 90 days and to notify relevant congressional committees within one business day when FDA receives a positive finished-product test or issues an actionable inspection classification.